Edwards puts more focus on heart valves after $140m LifeStent sale to Bard
This article was originally published in Clinica
Edwards Lifesciences has agreed to sell its LifeStent peripheral vascular product line to CR Bard for $140m. Edwards will receive an initial cash payment of $75m, plus $65m cash upon the achievement of certain milestones, including US regulatory approval of another indication for the product.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”